Berenberg slashes target price on Angle
Analysts at Berenberg slashed their target price on liquid biopsy specialist
Angle released a FY24 trading update on Tuesday morning, in which it said it now expects to deliver revenues of £2.9m - just below the lower end of its H1 guidance range - with its loss for the year expected to be in line with guidance.
Given the decline in revenues reported in H1, Berenberg said it was "encouraging" to see a return to growth in H2 and that management appears positive on the trajectory for FY25.
"Looking ahead, we expect further progress and expansion of the company's existing large pharma partnerships in 2025E and 2026E, with the possibility of further partnership deals to accelerate growth in the medium term," said the German bank, which has a 'buy' rating on the stock.
"For 2026E, ANGLE trades on 5x EV/sales. Our 40p price target is based on a risk-adjusted NPV (rNPV) approach. The reduction to our price target is largely the result of lower estimates."
Reporting by Iain Gilbert at Sharecast.com
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.